New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2025

WU Qixian; LIANG Chen; YU Xianjun

doi:10.19401/j.cnki.1007-3639.2026.01.001

您当前的位置：

首页 >

文章列表页 >

New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2025

Specialist's Commentary | 更新时间：2026-04-17

- New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2025
- China Oncology Vol. 36, Issue 1, Pages: 1-26(2026)
- 作者机构：
  
  复旦大学附属肿瘤医院胰腺外科，复旦大学上海医学院肿瘤学系，复旦大学胰腺肿瘤研究所，上海市胰腺肿瘤研究所，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2026.01.001
  CLC： R735.9
- Received：29 December 2025，
  
  Revised：2026-01-29，
  
  Accepted：29 January 2026，
  
  Published：30 January 2026
- 稿件说明：
移动端阅览
WU Qixian, LIANG Chen, YU Xianjun. New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2025[J]. China Oncology, 2026, 36(1): 1-26.
DOI：

WU Qixian, LIANG Chen, YU Xianjun. New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2025[J]. China Oncology, 2026, 36(1): 1-26. DOI： 10.19401/j.cnki.1007-3639.2026.01.001.

摘要

胰腺癌是预后极差的消化系统恶性肿瘤之一，其发病率和死亡率持续上升。2025年，胰腺癌在流行病学、基础研究及诊疗策略方面均取得了一系列重要进展。流行病学研究进一步明确了酒精摄入、糖尿病、代谢异常、胰内脂肪沉积、口腔微生物组及药物暴露等因素与胰腺癌发生风险之间的相关性，并推动基于新发糖尿病等人群的风险分层与早期筛查策略的发展。基础研究方面，围绕肿瘤微环境、免疫逃逸、代谢重编程、基质力学特性及神经-免疫相互作用等关键问题，揭示了调控胰腺癌发生、发展及治疗耐受的新分子机制。同时，KRAS靶向治疗、代谢-免疫联合干预、细胞治疗及纳米免疫策略等取得突破性进展，为将“免疫冷肿瘤”转化为“免疫热肿瘤”提供了新的理论基础。临床与转化研究不断推进精准分层、联合治疗及新型免疫治疗策略的探索。本文系统性综述2025年度胰腺癌研究及诊疗领域的重要进展，强调其对早期风险识别、机制驱动治疗及精准医学实践的启示，以期为胰腺癌的基础研究和临床决策提供参考。

Abstract

Pancreatic cancer is one of the malignant tumors of the digestive system with a poor prognosis

and its incidence and mortality rates continue to rise. In 2025

substantial advances have been made in the epidemiology

basic research and clinical management of pancreatic cancer. Epidemiological studies have further clarified the associations between pancreatic cancer risk and alcohol consumption

diabetes

metabolic abnormalities

intrapancreatic fat deposition

oral microbiota

and medication exposure

while promoting risk stratification and early detection strategies based on new-onset diabetes and other high-risk populations. In basic research

emerging studies have uncovered novel mechanisms underlying tumor progression

immune evasion

and therapeutic resistance

with particular emphasis on the tumor microenvironment

metabolic reprogramming

stromal mechanics

and neuro-immune interactions. Meanwhile

major breakthroughs have been achieved in KRAS-targeted therapies

metabolism-immunity combination strategies

cellular immunotherapy

and nanomedicine-based approaches

providing new avenues to convert pancreatic cancer from an immunologically "cold" to a "hot" tumor. Clinical and translational efforts continue to advance precision stratification and rational combination therapies. This review summarizes the key research and clinical advances in pancreatic cancer in 2025

highlighting their implications for early risk identification

mechanism-driven treatment strategies

and precision oncology.

关键词

Keywords

references

SIEGEL R L, KRATZER T B, GIAQUINTO A N, et al. Cancer statistics, 2025[J]. CA Cancer J Clin, 2025, 75(1): 10-45.

O'DOWD A. Alcohol is associated with increased risk of pancreatic cancer, finds study of 2.5m people[J]. BMJ, 2025, 389: r1117.

OYAMA H, HAMADA T, NEVO D, et al. Relationship of intrapancreatic fat deposition with pancreatic cancer differs according to carcinoma types[J]. Gastroenterology, 2025, 169 (4): 718-721. e5.

CHARI S T. Diabetes and pancreatic cancer: a complex and confounding interplay[J]. Gut, 2025: gutjnl-2025-336806.

TAN J T, MAO X H, LUI D T, et al. Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort study[J]. Gut, 2025, 75(1): 94-104.

TAN J T, MAO X H, CHENG H M, et al. Aspirin is associated with lower risk of pancreatic cancer and cancer-related mortality in patients with diabetes mellitus[J]. Gut, 2025, 74(4): 603-612.

MENG Y X, WU F, KWAK S, et al. Oral bacterial and fungal microbiome and subsequent risk for pancreatic cancer[J]. JAMA Oncol, 2025, 11(11): 1331-1340.

HAMADA T, OYAMA H, NEVO D, et al. Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance: a prospective longitudinal cohort study[J]. Gut, 2025, 74(6): 971-982.

FLEMING MARTINEZ A K, DÖPPLER H R, ARGO R, et al. Downregulation of Sod2 increases atypical flat lesions and dysplasia to advance pancreatic ductal adenocarcinoma[J]. Mol Cancer, 2025, 24(1): 300.

BODAS C, FELIPE I, CHANEZ B, et al. A Common CTRB misfolding variant associated with pancreatic cancer risk causes ER stress and inflammation in mice[J]. Gut, 2025, 74(9): 1452-1466.

ZHONG J, O'BRIEN A, PATEL M B, et al. Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma [J ] . Gut, 2025: gutjnl-gu2025-335152.

FANG Z, WU Z, YU C, et al. EIF4E-mediated biogenesis of circPHF14 promotes the growth and metastasis of pancreatic ductal adenocarcinoma via Wnt/β-catenin pathway[J ] . Mol Cancer, 2025, 24(1): 56.

XU Y, PENG X L, EAST M P, et al. Tumor-intrinsic kinome landscape of pancreatic cancer reveals new therapeutic approaches[J]. Cancer Discov, 2025, 15(2): 346-362.

MULLEN K M, HONG J, ATTIYEH M A, et al. The evolutionary forest of pancreatic cancer[J]. Cancer Discov, 2025, 15(2):329-345.

BANDI D S R, NAGARAJU G P, SARVESH S, et al. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma[J]. Mol Cancer, 2025, 24(1): 76.

RUBINSON D A, TANAKA N, FECE DE LA CRUZ F, et al. Sotorasib is a pan-RAS G12C inhibitor capable of driving clinical response in NRAS G12C cancers[J ] . Cancer Discov, 2024, 14(5):727-736.

MCANDREWS K M, PARADISO F, STALNECKER C A, et al. An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer[J]. Sci Transl Med, 2025, 17(814): eadt5511.

RAO S V, YOUNG L, CHEESEMAN D, et al. Transcription factor switching drives subtype-specific pancreatic cancer[J]. Nat Genet, 2025, 57(12): 3016-3026.

EKSTROM T L, ROSOK R M, ABDELRAHMAN A M, et al. Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase Ⅱ pause release to modulate classical subtype identity in pancreatic cancer[J]. Gut, 2025, 74(7): 1112-1124.

LI H F, LAN L X, CHEN H X, et al. SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer[J]. Nature, 2025, 648(8092): 203-209.

SMITH S J, MENG F, LINGEMAN R G, et al. Therapeutic targeting of oncogene-induced transcription-replication conflicts in pancreatic ductal adenocarcinoma [J]. Gastroenterology, 2025, 169(4): 600-614.e11.

ZHAO Z P, LI Q, QU C H, et al. A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer[J]. Nat Nanotechnol, 2025, 20(8): 1131-1141.

LOU X, SHI Y H, ZHAO F M, et al. Pancreatic neuroendocrine tumors secrete apolipoprotein E to induce tip endothelial cells that remodel the tumor-stroma ratio and promote cancer progression[J]. Cancer Res, 2025, 85(15): 2805-2819.

ZHANG Y J, LING L, MURAD R, et al. Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer[J]. Cancer Cell, 2025, 43(9): 1677-1696.e15.

RONG Z Y, YANG J H, LIU J, et al. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer[J]. Int J Surg, 2025, 111(2): 1891-1903.

TANG R, ZHANG Z F, LIU X M, et al. Stromal stiffness-regulated IGF 2 BP 2 in pancreatic cancer drives immune evasion via sphingomyelin metabolism[J ] . Gastroenterology, 2025, 169 (4): 615-631.e32.

AHMED A, SPRINGFELD C, HALAMA N. De novo induction of tertiary lymphoid structures: an immunotherapeutic strategy in pancreatic cancer[J ] . Signal Transduct Target Ther, 2025, 10 (1): 173.

SHAO S Y, CHEN X H, CHEN Y X, et al. STING-activating pyroptotic nanoparticles for in situ pancreatic cancer vaccination and immunotherapy[J ] . Sci Bull, 2025, 70(11): 1753-1756.

SHAKIBA M, TUVESON D A. Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer[J]. Nat Immunol, 2025, 26(5): 678-691.

ESPINET E, NATOLI G. Leveraging the tug-of-war with genomic retroelements to enhance immunotherapy of pancreatic cancer[J]. Gut, 2025, 74(5): 701-702.

FINCHAM R E A, PERIASAMY P, JOSEPH C R, et al. The interplay between natural killer cells and pancreatic stellate cells in pancreatic ductal adenocarcinoma[J]. Cancer Commun, 2025, 45(2): 172-177.

RAJESH C, CUMMINGS R D, RADHAKRISHNAN P. Unraveling the glyco-immunity nexus in pancreatic cancer[J]. Mol Cancer, 2025, 24(1): 211.

ROUSSEAU L, HO P C. Adipose whispers to mast cells for accelerating immune evasion in pancreatic cancer[J]. Cell Metab, 2025, 37(12): 2296-2297.

LAO M Y, ZHANG X Z, LI Z J, et al. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy[J]. Cancer Commun, 2025, 45 (8): 1010-1037.

XUE C L, ZHAO S H, ZHOU Y F, et al. Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy[J]. Cell Metab, 2025, 37(12): 2381-2401.e9.

LASSE OPSAHL E L, PASCA DI MAGLIANO M. Two shots on goal: combination of RAS inhibition and immunotherapy drives long-term remission in pancreatic cancer[J]. Cancer Discov, 2025, 15(8): 1537-1539.

LIU Y H, HAN J C, HSU W H, et al. Combined KRAS inhibition and immune therapy generates durable complete responses in an autochthonous PDAC model[J]. Cancer Discov, 2025, 15(1):162-178.

ELY Z A, KULSTAD Z J, GUNAYDIN G, et al. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition[J]. Science, 2025, 388(6747): eadk3487.

YANG D W, SUN X L, WANG H, et al. TREM2 depletion in pancreatic cancer elicits pathogenic inflammation and accelerates tumor progression via enriching IL-1β(+ ) macrophages[J ] . Gastroenterology, 2025, 168(6): 1153-1169.

CHEN X, FU H T, ZHU S M, et al. The moonlighting function of glutaminase 2 promotes immune evasion of pancreatic ductal adenocarcinoma by tubulin tyrosine ligase-like 1-mediated Yes1 associated transcriptional regulator glutamylation [J]. Gastroenterology, 2025, 168(6): 1137-1152.

RUSSELL S N, DEMETRIOU C, VALENZANO G, et al. Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control[J ] . Gut, 2025, 74(5): e333492.

KIM H S, KIM J Y, LEE J Y, et al. Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma[J]. J Hematol Oncol, 2025, 18(1): 100.

WANG K Y, NI B, XIE Y J, et al. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells[J]. Cell Res, 2025, 35(5): 362-380.

YANG J, YU X N, XIAO M M, et al. Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer[J]. Gut, 2025, 74(11): e334361.

LIU X W, SONG J N, YUAN M L, et al. Single-cell transcriptional dissection illuminates an evolution of immunosuppressive microenvironment during pancreatic ductal adenocarcinoma metastasis[J]. Signal Transduct Target Ther, 2025, 10(1): 182.

MAHAT D B, KUMRA H, CASTRO S A, et al. Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer[J]. Immunity, 2025, 58(7): 1688-1705.e9.

CHEN E H, WANG Q, WANG L S, et al. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway[J ] . Cancer Commun, 2025, 45(9): 1162-1187.

WANG C, HOU Y C, HONG Y K, et al. Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS -mutated pancreatic cancer cells[J ] . Mol Cancer, 2025, 24(1): 25.

CUI M, MO S W, BAI J L, et al. Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer[J]. Gut, 2025:gutjnl-gu2025-336117.

BRODERICK C, MEZZADRA R, SISSO E M, et al. A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in pancreatic ductal adenocarcinoma[J]. Cancer Discov, 2025, 15(8): 1717-1739.

ORLEN M, VOSTREJS W P, SOR R, et al. T-cell dependency of tumor regressions and complete responses with RAS(ON)multi-selective inhibition in preclinical models of pancreatic ductal adenocarcinoma[J]. Cancer Discov, 2025, 15(8): 1697-1716.

CHEN J J, MA F H, CHEN Y J, et al. Synergistic therapy for pancreatic cancer by deactivating cancer-associated fibroblasts and driving T-cell migration into tumor microenvironment using nanochaperone delivery system[J]. Bioact Mater, 2025, 52:287-299.

AMISAKI M, ZEBBOUDJ A, YANO H, et al. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer [J]. Nature, 2025, 638(8052): 1076-1084.

CHEN H, LI M L, XIE F M, et al. A novel protein cPFKFB4 encoded by hsa_circ_0065394 strengthens PKM2-mediated glucose metabolic reprogramming to facilitate pancreatic cancer progression under hypoxia[J]. Mol Cancer, 2025, 24(1): 285.

LUO D, CHEN Q Z, LI Y X, et al. Microbiome-metabolome interplay in pancreatic cancer progression: insights from multi-omics analysis[J]. Mol Cancer, 2025, 24(1): 240.

DATTARO L. Pancreatic cancer is evasive. is the nervous system the reason why [J]. Nature, 2025, 648(8093): S49-S50.

QIN J Q, LIU J J, WEI Z H, et al. Targeted intervention in nerve-cancer crosstalk enhances pancreatic cancer chemotherapy[J]. Nat Nanotechnol, 2025, 20(2): 311-324.

CHEN M M, GAO Q H, NING H H, et al. Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer[J]. Cancer Cell, 2025, 43(9): 1656-1676.e10.

PANDA A, RAGUNATH K, PAJIC M, et al. Oncogenic proteome of pancreatic cancer extracellular vesicles: sodium/myo-inositol cotransporter as a potential marker[J]. Signal Transduct Target Ther, 2025, 10(1): 148.

KOLARZYK A M, KWON Y, OH E, et al. Non-canonical ALK7 pathways promote pancreatic cancer metastasis through β-catenin/MMP-mediated basement membrane breakdown and intravasation[J]. Mol Cancer, 2025, 24(1): 188.

CRAWFORD K J, HUMPHREY K S, CORTES E, et al. Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma[J]. bioRxiv, 2025. DOI:10.1101/2025.02.06.636643.

CHALABI HAJKARIM M, MAY M, AMIN A D, et al. Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma[J]. Nat Genet, 2025, 57(11): 2728-2742.

YAO L L, QIN W T, HU L P, et al. Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adenocarcinoma[J]. Cancer Commun, 2025, 45(2): 143-166.

TAN Z, YANG J H, CHEN Y Y, et al. M(6)a demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis[J]. Cell Death Dis, 2025, 16(1): 784.

DING J S, XIE Y J, LIU Z Y, et al. Hypoxic and acidic tumor microenvironment-driven AVL9 promotes chemoresistance of pancreatic ductal adenocarcinoma via the AVL9-IκBα-SKP1 complex[J ] . Gastroenterology, 2025, 168(3): 539-555.e5.

ZHANG S P, DENG S, LIU J, et al. Targeting MXD1 sensitises pancreatic cancer to trametinib[J]. Gut, 2025, 74(8): 1262-1278.

ZHANG J, LV S N, PENG X Y, et al. CircERC1 facilitates chemoresistance through inhibiting pyroptosis and remodeling extracellular matrix in pancreatic cancer[J]. Mol Cancer, 2025, 24(1): 185.

ZHANG C, CHEN Y H, ZHU S C, et al. Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy[J]. Drug Resist Updat, 2025, 83: 101292.

RACHAMALA H K, NAKKA N M R, ANGOM R S, et al. Dual targeting of syndecan-1 and glucose transporter-1 with a novel lipid-based delivery system enhances therapeutic efficacy and overcomes chemoresistance in pancreatic ductal adenocarcinoma [J]. Gastroenterology, 2025, 168(1): 160-163.e4.

NUWER R. The pancreatic cancer models helping to drive innovation in the field[J]. Nature, 2025, 648(8093): S51-S53.

LEE J H, LEE C G, KIM M S, et al. Deeply implantable, shape-morphing, 3D MicroLEDs for pancreatic cancer therapy[J]. Adv Mater, 2025, 37(49): e2411494.

SUN Y, XIE W H, SHI F Y, et al. Mesoporous high-entropy oxides nanoplatform decodes paired-plasma metabolic fingerprinting of pancreatic cancer[J]. Adv Mater, 2025: e13988.

QIAO C Q, WANG L X, HUANG C T, et al. Engineered bacteria manipulate cysteine metabolism to boost ferroptosis-based pancreatic ductal adenocarcinoma therapy[J]. Adv Mater, 2025, 37(6): e2412982.

KIM J S, PARK C H, KIM E, et al. Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer[J]. Mol Cancer, 2025, 24(1): 162.

MELLE F, MENON D, CONNIOT J, et al. Rational design of metal-organic frameworks for pancreatic cancer therapy: from machine learning screening to in vivo efficacy[J ] . Adv Mater, 2025, 37(52): 2412757.

YI S, NOH K, KIM H, et al. Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation[J]. Mol Cancer, 2025, 24(1): 124.

SONG N C, LI H J, TAO R Y, et al. A smart DNA nanoframework enables synergistic photodynamic therapy of pancreatic cancer[J]. Adv Mater, 2025, 37(30): e2416161.

YOU E, PATEL B K, ROJAS A S, et al. LINE-1 ORF1p mimics viral innate immune evasion mechanisms in pancreatic ductal adenocarcinoma[J]. Cancer Discov, 2025, 15(5): 1063-1082.

XIAO M M, TANG R, PAN H Q, et al. TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality[J]. Gut, 2025, 74(3):e332782.

DING Y H, BAI Y P, CHEN T Y, et al. Disruption of the sorcin-PAX5 protein-protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer[J]. J Hematol Oncol, 2025, 18(1): 27.

HE Z W, ZHENG D J, LI F T, et al. TMOD3 accelerated resistance to immunotherapy in KRAS -mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4[J ] . Drug Resist Updat, 2025, 78: 101171.

LIN H Y, ZHU S C, CHEN Y H, et al. Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer[J]. Drug Resist Updat, 2025, 81: 101240.

STOOP T F, JAVED A A, OBA A, et al. Pancreatic cancer[J]. Lancet, 2025, 405(10485): 1182-1202.

HEDLEY E. A breathalyser-style test for detecting pancreatic cancer[J]. Nature, 2025, 648(8093): S57.

WILLYARD C. Early detection could improve pancreatic cancer's poor survival rates[J]. Nature, 2025, 648(8093): S54-S56.

YIN L D, CAO C, LIN J Z, et al. Development and validation of a cell-free DNA fragmentomics-based model for early detection of pancreatic cancer[J]. J Clin Oncol, 2025, 43(26): 2863-2874.

PERRI G, MARCHEGIANI G. Introducing 'borderline observable' intraductal papillary mucinous neoplasms: between pancreatic cancer risk and discontinuation of extended surveillance[J]. Gut, 2025, 74(12): 1940-1941.

RANGELOVA E, STOOP T F, VAN RAMSHORST T M E, et al. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study [J]. Ann Oncol, 2025, 36(5): 529-542.

JANSSEN Q P, VAN DAM J L, VAN BEKKUM M L, et al. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial[J]. Lancet Oncol, 2025, 26(10): 1346-1356.

BAI X L, LI X, CHEN Y W, et al. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: a randomized phase 3 trial[J]. Cancer Cell, 2025, 43(12): 2259-2267.e2.

LI Z, SHI Y H, ZHUO Q F, et al. Main pancreatic duct exposure, repair, or reconstruction during minimally invasive pancreatic enucleation: a long-term metabolic outcome from a prospective cohort study (CSPAC-MIEN-1)[J]. Int J Surg, 2025, 111(11):8001-8014.

EVANS D B, ERICKSON B A, HALL W A. Local disease control in patients with pancreatic cancer[J]. JAMA Oncol, 2025, 11(6): 617-618.

REYNGOLD M, SCHOENFELD J D, O'REILLY E M, et al. Nonoperative management of technically resectable pancreatic cancer with ablative radiation therapy[J]. JAMA Oncol, 2025, 11 (6): 609-616.

NICHETTI F, PROCACCIO L, LONARDI S, et al. Chemotherapy for locally advanced pancreatic cancer: the dilemma of David versus Goliath after NEOPAN[J]. J Clin Oncol, 2026, 44(2): 130-131.

FIETKAU R, GHADIMI M, GRÜTZMANN R, et al. Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer:the randomized CONKO-007 trial[J]. J Clin Oncol, 2025, 43 (30): 3266-3278.

CHEN I M, JOHANSEN J S, THEILE S, et al. Randomized phase Ⅱ study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in advanced pancreatic cancer: Survival and cachexia[J]. J Clin Oncol, 2025, 43(18): 2107-2118.

LU Y X, LIN Q G, MO Y X, et al. Efficacy and safety of TAS-102 plus surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study[J]. Mol Cancer, 2025, 24(1): 235.

KAMGAR M, KO A H. Bridging the gap: Molecular profiling to guide treatment selection in metastatic pancreatic cancer[J]. J Clin Oncol, 2025, 43(31): 3334-3338.

SEUFFERLEIN T. Personalizing chemotherapy in metastatic pancreatic cancer[J]. J Clin Oncol, 2025, 43(31): 3327-3330.

WANG Y X, KONG F C, SITU X, et al. Defining homologous recombination deficiency status in pancreatic ductal adenocarcinoma: clinical implications for evaluating response to platinum chemotherapy[J]. Drug Resist Updat, 2025, 83:101291.

YOUSEF M, YOUSEF A, HURD M W, et al. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma [J ] . J Hematol Oncol, 2025, 18(1): 44.

LAHUSEN A, LUTZ M P, FANG R, et al. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial[J]. Mol Cancer, 2025, 24(1): 202.

VEENSTRA C M, ABRAHAMSE P, HAMILTON A S, et al. Breast, colorectal, and pancreatic cancer mortality with pathogenic variants in ATM , CHEK2 , or PALB2 [J ] . J Clin Oncol, 2025, 43(13): 1587-1596.

XUE N N, SABROSO-LASA S, MERINO X, et al. A fusion-based deep-learning algorithm predicts PDAC metastasis based on primary tumour CT images: a multinational study[J]. Gut, 2025, 74(12): 2024-2034.

Bespoke vaccines can elicit long-lived immune activity against pancreatic cancer[J]. Nature, 2025.[Epub ahead of print]

TAN Q, LI Y F, LIU C X, et al. Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: a phase 1b/2 trial[J]. Signal Transduct Target Ther, 2025, 10(1): 381.

JIA R, SI H Y, FAN M J, et al. First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ⅰb/Ⅱrandomized study[J]. Signal Transduct Target Ther, 2025, 10: 339.

KING A. Therapeutic vaccines can challenge pancreatic cancer before it takes hold[J]. Nature, 2025, 648(8093): S58-S60.

SETHNA Z, GUASP P, REICHE C, et al. RNA neoantigen vaccines prime long-lived CD8 + T cells in pancreatic cancer[J ] . Nature, 2025, 639(8056): 1042-1051.

SHUI L S, WESTCOTT P M K. Personalized syringes offer hope for pancreatic cancer patients[J]. Immunity, 2025, 58(5): 1182-1184.

SHI S, ZHANG J, LIU R J, et al. A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer[J]. Cell Rep Med, 2025, 6(10): 102364.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2024

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023

Precision therapy in pancreatic cancer: from streamlet towards mainstream

New strategies for combined with immunotherapy of clear cell renal cell carcinoma: advances in aerobic glycolysis

Related Author

Hao LIU

Junjie SU

Shiyong XIN

Ting WANG

Yi QIN

Xiaowu XU

Xianjun YU

Tianjiao LI

Related Institution

College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology

Department of Urology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai Key Laboratory of Precision Medicine for Pancreatic Cancer, Pancreatic Cancer Institute, Fudan University

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center

AI脑图

AI问答

⁰